The UK’s National Institute for Health and Care Excellence (NICE) has today published draft guidance that does not recommend Swiss pharma giant Roche’s (ROG: SIX) Gazyvaro/Gazyva (obinutuzumab) with bendamustine for treating some people with follicular lymphoma – a type of non-Hodgkin’s lymphoma.
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment with, rituximab – containing regimens (current standard treatment that targets lymphoma cells).
The NICE appraisal committee concluded that there were uncertainties in the evidence for obinutuzumab with bendamustine which meant that the overall survival gain of patients was unclear, so could not recommend the drug as a cost-effective use of NHS resources. The committee noted that an updated analysis from the pivotal trial for the drug will soon be available.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze